Ampio Pharmaceuticals (AMPE) 10-Q 8 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	1-May-15
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	AMPE
Entity Registrant Name	AMPIO PHARMACEUTICALS, INC.
Entity Central Index Key	1411906
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		51,987,890

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$43,271,458	$50,320,656
Prepaid expenses and other	283,737	672,716
Prepaid research and development - related party (Note 7)	265,785	265,785
Total current assets	43,820,980	51,259,157
Fixed assets, net (Note 2)	9,819,789	9,945,428
In-process research and development	7,500,000	7,500,000
Patents, net	646,472	664,169
Long-term portion of prepaid research and development - related party (Note 7)	797,356	863,802
Deposits	35,854	35,854
Total noncurrent assets	18,799,471	19,009,253
Total assets	62,620,451	70,268,410
Current liabilities
Accounts payable	1,521,317	3,299,025
Accrued compensation	537,594	235,665
Deferred rent	59,579	59,579
Deferred revenue	85,714	85,714
Total current liabilities	2,204,204	3,679,983
Long-term deferred rent	654,874	661,160
Long-term deferred revenue	447,321	468,749
Total liabilities	3,306,399	4,809,892
Commitments and contingencies (Note 4)
Stockholders' equity
Preferred Stock, par value $.0001; 10,000,000 shares authorized; none issued
Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued and outstanding - 51,986,534 in 2015 and 51,972,266 in 2014	5,199	5,197
Additional paid-in capital	169,555,230	168,108,278
Advances to stockholders	-90,640	-90,640
Accumulated deficit	-109,188,153	-101,904,570
Total Ampio stockholders' equity	60,281,636	66,118,265
Non-controlling interests	-967,584	-659,747
Total equity	59,314,052	65,458,518
Total liabilities and equity	$62,620,451	$70,268,410

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred Stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	0	0
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	51,986,534	51,972,266
Common Stock, shares outstanding	51,986,534	51,972,266

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
License revenue	$21,429	$12,500
Expenses
Research and development	4,576,268	7,794,408
Research and development - related party (Note 7)	83,948	34,577
General and administrative	2,961,058	2,658,772
Total operating expenses	7,621,274	10,487,757
Other income
Interest income	8,425	3,495
Total other income	8,425	3,495
Net loss	-7,591,420	-10,471,762
Net loss applicable to non-controlling interests	307,837	229,579
Net loss applicable to Ampio	($7,283,583)	($10,242,183)
Weighted average number of Ampio common shares outstanding	51,981,340	44,950,267
Basic and diluted Ampio net loss per common share	($0.14)	($0.23)

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid in Capital [Member]	Advances to Stockholders [Member]	Accumulated Deficit [Member]	Non-controlling Interest [Member]
	USD ($)	Series A Preferred Stock [Member]	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)
Beginning Balance at Dec. 31, 2014	$65,458,518		$5,197	$168,108,278	($90,640)	($101,904,570)	($659,747)
Beginning Balance, shares at Dec. 31, 2014			51,972,266
Common stock issued for services	30,000		1	29,999
Common stock issued for services, shares			7,998
Warrants exercised, net	1		1
Warrants exercised, net, shares			6,270
Stock-based compensation	1,416,953			1,416,953
Stock-based compensation, shares	0	0	0	0	0	0	0
Net loss	-7,591,420					-7,283,583	-307,837
Ending Balance at Mar. 31, 2015	$59,314,052		$5,199	$169,555,230	($90,640)	($109,188,153)	($967,584)
Ending Balance, shares at Mar. 31, 2015			51,986,534

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($7,591,420)	($10,471,762)
Stock-based compensation expense	1,416,953	1,021,231
Depreciation and amortization	231,008	41,216
Amortization of prepaid research and development - related party (Note 7)	66,446	11,075
Common stock issued for services	30,000	30,000
Adjustments to reconcile net loss to net cash used in operating activities:
Decrease (increase) in prepaid expenses and other	388,979	-363,317
(Increase) in prepaid research and development - related party (Note 7)		-1,340,000
(Decrease) increase in accounts payable	-1,822,318	2,521,845
Increase in accrued liabilities - related party (Note 7)		600,000
(Decrease) in deferred rent	-6,286
(Decrease) in deferred revenue	-21,429	-12,500
Increase (decrease) in accrued compensation	301,929	-522,056
Net cash used in operating activities	-7,006,139	-8,484,268
Cash flows used in investing activities:
Purchase of fixed assets	-43,060	-3,042,203
Net cash used in investing activities	-43,060	-3,042,203
Cash flows from financing activities:
Proceeds from sale of common stock		68,442,553
Costs related to sale of common stock		-4,999,777
Net cash provided by financing activities	1	63,442,776
Net change in cash and cash equivalents	-7,049,198	51,916,305
Cash and cash equivalents at beginning of period	50,320,656	26,309,449
Cash and cash equivalents at end of period	43,271,458	78,225,754
Non-cash transactions:
Fixed asset purchases included in accounts payable	$44,612

Basis_of_Presentation_and_Busi

Basis of Presentation and Business	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation and Business	Note 1 – Basis of Presentation and Business
	Basis of Presentation
	These unaudited financial statements represent the consolidated financial statements of Ampio Pharmaceuticals, Inc. (“Ampio” or “the Company”), and its wholly-owned subsidiaries, Vyrix Pharmaceuticals, Inc. (“Vyrix”) and Luoxis Diagnostics, Inc. (“Luoxis”), an 80.9% owned subsidiary. These unaudited consolidated financial statements should be read in conjunction with Ampio’s Annual Report on Form 10-K for the year ended December 31, 2014, which included all disclosures required by generally accepted accounting principles. In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary to present fairly the financial position of Ampio and its subsidiaries on a consolidated basis and the consolidated results of operations and cash flows for the interim periods presented. The results of operations for the period ended March 31, 2015 are not necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the period ended March 31, 2015 is unaudited. Ampio’s activities, being primarily research and development and raising capital, have not generated significant revenue to date.
	Newly Issued Accounting Pronouncements
	In January 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-01, “Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.” The purpose of this amendment is to eliminate the concept of extraordinary items. As a result, an entity will no longer be required to separately classify, present and disclose extraordinary events and transactions. The amendment is effective for annual reporting periods beginning after December 15, 2015 and subsequent interim periods with early application permitted. Management is currently assessing the impact the adoption of ASU 2015-01 will have on our financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods beginning after December 15, 2016, with early adoption permitted. Management is currently assessing the impact the adoption of ASU 2014-15 will have on our financial statements.
	In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, “Revenue from Contracts with Customers”. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance will be effective for annual reporting periods beginning after December 15, 2016. Early adoption is not permitted. We are currently evaluating the accounting, transition and disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption.
	Business
	Ampio is a biopharmaceutical company focused primarily on developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depleting available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability. We are also focused on monetizing our sexual dysfunction portfolio and diagnostic platform.
	Error in Classification
	Patent costs were previously classified as research and development, however, it was determined that these costs were incorrectly classified and, therefore, have been reclassified as general and administrative expense for all periods presented. Patent costs consist of legal and filing fees related to obtaining and maintaining patents and should have been excluded from research and development activities as set forth in the FASB’s Accounting Standards Codification Topic 730, Research and Development. The impact of the correction of this error in classification decreased research and development expenses and correspondingly increased general and administrative expenses for the three months ended March 31, 2014 by $609,000. The correction of this error had no impact on our total operating expenses or our net loss for any periods presented.

Fixed_Assets

Fixed Assets	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 2 – Fixed Assets
	Fixed assets are recorded at cost and, once placed in service, are depreciated on the straight-line method over the estimated useful lives. Fixed assets consist of the following:
		Estimated Useful	As of			As of
		Lives in years	March 31, 2015			December 31, 2014
	Manufacturing Facility/Clean Room - in progress	8	$	2,746,000		$	2,684,000
	Leasehold improvements	10		6,075,000			6,064,000
	Office furniture and equipment	3 - 10		556,000			556,000
	Lab equipment	5		1,076,000			1,060,000
	Less accumulated depreciation and amortization			(633,000	)		(419,000	)
	Fixed assets, net		$	9,820,000		$	9,945,000

License_AgreementRevenue_Recog

License Agreement/Revenue Recognition	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
License Agreement/Revenue Recognition	Note 3 – License Agreement/Revenue Recognition
	We have not generated material revenue in our operating history. The $21,000 and $13,000 license revenue recognized in the 2015 quarter and 2014 quarter, respectively, represents the amortization of the upfront payments received on our license agreements. The initial payment of $500,000 from the license agreement of Zertane with a Korean pharmaceutical company was deferred and is being recognized over ten years. The initial payment of $250,000 from the license agreement of Zertane with a Canadian-based supplier was deferred and is being recognized over seven years.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 4 – Commitments and Contingencies
	Commitments and contingencies are described below and summarized by the following table:
		Total		Remaining		2016		2017		2018		2019		Thereafter
				2015
	Ampion supply agreement	$	9,799,000	$	2,149,000	$	2,550,000	$	2,550,000	$	2,550,000	$	—	$	—
	Clinical research and trial obligations		4,793,000		4,793,000		—		—		—		—		—
	Sponsored research agreement with related party		1,300,000		244,000		325,000		325,000		325,000		81,000		—
	Facility lease		3,147,000		223,000		297,000		306,000		316,000		326,000		1,679,000
		$	19,039,000	$	7,409,000	$	3,172,000	$	3,181,000	$	3,191,000	$	407,000	$	1,679,000
	Manufacturing Facility/Clean Room – In Progress
	The manufacturing facility/clean room is expected to provide commercial scale, FDA compliant, GMP manufacturing of Ampion, an advanced research and development laboratory as well as sufficient office space to consolidate the core operations of the Company in a single facility.
	Ampion Supply Agreement
	In connection with the manufacturing facility/clean room, in October 2013, Ampio entered into a human serum albumin ingredient and purchase sale agreement with a remaining commitment of $9,799,000.
	Clinical Research and Trial Obligations
	In connection with upcoming clinical trials, as of March 31, 2015, Ampio has a remaining commitment of $2,000,000 on contracts related to the Ampion study trial expense and $2,793,000 remaining contract commitments related to the Optina study trial expense.
	Sponsored Research Agreement with Related Party
	Ampio entered into a Sponsored Research Agreement with TRLLC, a related party, in September 2009. Under the terms of the Sponsored Research Agreement, Ampio is to provide personnel and pay for leased equipment. The Sponsored Research Agreement may be terminated without cause by either party on 180 days’ notice. As further noted in Note 7 – Related Party Transactions, in March 2014, the Sponsored Research Agreement was extended through March 2019, including a “no termination” period through March 2017. In a subsequent Addendum, the parties also agreed to increase the equivalent value of the personnel provided by Ampio from $264,000 to $325,000 per year.
	Facility Lease
	On December 13, 2013, Ampio entered into a 125 month non-cancellable operating lease for new office space and the manufacturing facility effective May 1, 2014. The new lease has initial base rent of $23,000 per month, with the total base rent over the term of the lease of approximately $3.3 million and includes rent abatements and leasehold incentives. The Company recognizes rental expense of the facility on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. Rent expense for the respective periods is as follows:
		Three Months Ended March 31,
		2015		2014
	Rent expense	$	67,000	$	30,000

Common_Stock

Common Stock	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Common Stock	Note 5 – Common Stock
	Capital Stock
	At March 31, 2015 and December 31, 2014, Ampio had 100.0 million shares of common stock authorized with a par value of $0.0001 per share and 10.0 million shares of preferred stock authorized with a par value of $0.0001 per share.
	Shelf Registration
	In December 2013, Ampio filed an additional shelf registration statement on Form S-3 with the Securities and Exchange Commission to register Ampio common stock and warrants in an aggregate amount of up to $100.0 million for offering from time to time in the future, as well as 1.5 million shares of common stock available for sale by selling shareholders. The shelf registration was declared effective in January 2014 by the Securities and Exchange Commission. As a result of equity raises, approximately $86.3 million remains available under the Form S-3 filed in December 2013.
	Underwritten Public Offerings
	In March 2014, Ampio completed an underwritten public offering for the sale of 9,775,000 shares of common stock at a price of $7.00 per share. Gross proceeds to the Company were $68.4 million with net proceeds of $63.4 million after underwriter fees and cash offering expenses.
	Common Stock Issued for Services
	Ampio issued 7,998 and 4,209 shares valued at $30,000 for non-employee directors as part of their director fees for the three months ended March 31, 2015 and 2014, respectively.

Equity_Instruments

Equity Instruments	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity Instruments	Note 6 – Equity Instruments
	Options
	In 2010, Ampio shareholders approved the adoption of a stock and option award plan (the “2010 Plan”), under which shares were reserved for future issuance under restricted stock awards, options, and other equity awards. The 2010 Plan permits grants of equity awards to employees, directors and consultants. The shareholders have approved a total of 11.7 million shares reserved for issuance under the 2010 plan.
	Ampio has computed the fair value of all options granted using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. Ampio calculates its volatility assumption using the actual changes in the market value of our stock. Ampio has estimated a forfeiture rate of 5.0% based upon historical experience; this is an estimate of options granted that are expected to be forfeited or cancelled before becoming fully vested. Ampio estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. During the three months ended March 31, 2015, Ampio granted 30,000 options at a price of $3.46 to employees which represented the fair market value on date of the grants. Ampio has computed the fair value of all options granted during the three months ended March 31, 2015 using the following assumptions:
	Expected volatility		104	%
	Risk free interest rate		1.5	%
	Expected term (years)		5
	Dividend yield		0	%
	Ampio stock option activity is as follows:
		Number of			Weighted			Weighted Average		Aggregate Fair
		Options			Average			Remaining		Value
					Exercise Price			Contractual Life
	Outstanding December 31, 2014		6,568,248		$	3.82			7.66	$	17,090,000
	Granted		30,000		$	3.46
	Exercised		—		$	—
	Forfeited/Cancelled		—		$	—
	Outstanding March 31, 2015		6,598,248		$	3.82			7.15	$	17,169,000
	Exercisable at March 31, 2015		5,437,604		$	3.48			6.74	$	12,539,000
	Available for grant at March 31, 2015		3,717,773
	Stock options outstanding and exercisable at March 31, 2015 are summarized in the table below:
	Range of Exercise Prices	Number of			Weighted			Weighted Average
		Options			Average			Remaining
		Outstanding and			Exercise Price			Contractual Lives
		Exercisable
	$1.03 - $4.00		4,423,248		$	2.33			6.58
	$4.01 - $7.00		1,240,000		$	6.17			8.59
	$7.01 - $8.93		935,000		$	7.73			7.92
			6,598,248		$	3.82			7.15
	Pursuant to the Luoxis 2013 Stock Option Plan (the “2013 Plan”), 5.0 million shares of its common stock were reserved for issuance. Luoxis stock option activity is as follows:
		Number of			Weighted			Weighted Average		Aggregate Fair
		Options			Average			Remaining		Value
					Exercise Price			Contractual Life
	Outstanding December 31, 2014		2,835,000		$	1.19			8.85	$	2,541,000
	Granted		—		$	—
	Exercised		—		$	—
	Forfeited/Cancelled		—		$	—
	Outstanding March 31, 2015		2,835,000		$	1.19			8.61	$	2,541,000
	Exercisable at March 31, 2015		975,000		$	1			8.26	$	687,000
	Available for grant at March 31, 2015		2,165,000
	Vyrix has also adopted a 2013 Stock Option Plan (the “Vyrix 2013 Plan”) which reserved 5.0 million shares of its common stock for issuance to officers, employees and consultants. Vyrix stock option activity is as follows:
		Number of			Weighted			Weighted Average		Aggregate Fair
		Options			Average			Remaining		Value
					Exercise Price			Contractual Life
	Outstanding December 31, 2014		950,000		$	0.7			9.04	$	416,000
	Granted		—		$	—
	Exercised		—		$	—
	Forfeited/Cancelled		—		$	—
	Outstanding March 31, 2015		950,000		$	0.7			8.79	$	417,000
	Exercisable at March 31, 2015		475,000		$	0.7			8.79	$	208,000
	Available for grant at March 31, 2015		4,050,000
	Stock-based compensation expense related to the fair value of stock options was included in the consolidated statements of operations as research and development expenses and general and administrative expenses as set forth in the table below. Ampio and its subsidiaries determined the fair value as of the date of grant using the Black-Scholes option pricing model and expenses the fair value ratably over the vesting period. The following table summarizes stock-based compensation expense for the three months ended March 31, 2015 and 2014:
		Three Months Ended March 31,
		2015			2014
	Research and development expenses
	Stock options
	Ampio	$	608,000		$	638,000
	Luoxis		107,000			52,000
	Vyrix		8,000			29,000
	General and administrative expenses
	Common stock issued for services		30,000			30,000
	Stock options
	Ampio		537,000			299,000
	Luoxis		138,000			58,000
	Vyrix		19,000			(55,000	)
	$	1,447,000		$	1,051,000
Unrecognized expense at March 31, 2015
Ampio	$	2,623,000
Luoxis	$	1,129,000
Vyrix	$	194,000
Weighted average remaining years to vest
Ampio		1.07
Luoxis		2.23
Vyrix		1.79
Warrants
Ampio issued warrants in conjunction with its Senior Convertible Debentures, 2011 Private Placements and an underwritten public offering. A summary of all Ampio warrants is as follows:
	Number of			Weighted			Weighted Average
	Warrants			Average			Remaining
				Exercise Price			Contractual Life
Outstanding December 31, 2014		516,329		$	3.26			1.44
Warrants exercised - Private/Registered Direct Placements		(15,001	)	$	4.06
Outstanding March 31, 2015		501,328		$	3.24			1.16
Luoxis issued warrants to purchase 465,250 shares of common stock at a price of $1.00 exercisable one year after the final closing in connection with the private placement in May 2013. All of these warrants remain outstanding with a weighted average remaining contractual life of 3.17.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Note 7 – Related Party Transactions
	Ampio entered into a sponsored research agreement with TRLLC, an entity controlled by our director and Chief Scientific Officer, Dr. Bar-Or, in September 2009, which has been amended six times with the last amendment occurring in January 2015. Under the amended terms of the research agreement, Ampio will provide personnel with an equivalent value of $325,000 per year. With the fifth amendment, Ampio also paid a sum of $725,000 in 2014 which is being amortized over the contractual term of 60.5 months and is divided between current and long-term on the balance sheet. In return, TRLLC will assign any intellectual property rights it develops on our behalf under the research agreement and undertake additional activities to support Ampio’s commercial activities and business plan. This agreement is set to expire in March 2019 and cannot be terminated prior to March 2017.
	In June 2013, the TRLLC agreement was amended to include Luoxis. The agreement, which was amended again in January 2015, provides for Luoxis to pay $6,000 per month to TRLLC in consideration for services related to research and development of Luoxis’ Oxidation Reduction Potential platform. In March 2014, Luoxis also agreed to pay a sum of $615,000 which is being amortized over the contractual term of 60.5 months and is divided between current and long-term on the balance sheet; this amount has been paid in full. This agreement has the same termination and expiration as the agreement between Ampio and TRLLC.
	The Company has advances to one executive and three employees that were used to purchase stock in the Company when it was formed during 2010. These advances are non-interest bearing and due on demand and are classified as a reduction to stockholders’ equity. As of March 31, 2015 and December 31, 2014, advances of $91,000 to stockholders remained outstanding.

Segment_Information

Segment Information	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Segment Information	Note 8 – Segment Information
	We manage our Company and aggregate our operational and financial information in accordance with two reportable segments: Ampio and the combined Luoxis and Vyrix Company. The Ampio segment consists of our core biopharmaceuticals compounds and the clinical trials associated with them. The combined Luoxis and Vyrix Company contains our men’s health platform which consists of its diagnostic device platform and sexual dysfunction portfolio. Select financial information for our segments is as follows:
		Three Months Ended March 31,
		2015			2014
	Revenue:
	Ampio	$	—		$	—
	Combined Luoxis and Vyrix Company		21,000			13,000
	Consolidated revenue	$	21,000		$	13,000
	Consolidated net loss:
	Ampio	$	(5,749,000	)	$	(8,469,000	)
	Combined Luoxis and Vyrix Company		(1,842,000	)		(2,003,000	)
	Consolidated net loss		(7,591,000	)		(10,472,000	)
	Reconciliation of consolidated net loss attributable to Ampio:
	Net loss applicable to non-controlling interests		308,000			230,000
	Net loss attributable to Ampio	$	(7,283,000	)	$	(10,242,000	)
		March 31, 2015			December 31, 2014
	Total assets
	Ampio	$	52,419,000		$	61,326,000
	Combined Luoxis and Vyrix Company		10,202,000			8,942,000
	Total assets	$	62,621,000		$	70,268,000

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 9 – Subsequent Events
	On April 15, 2015, the Company modified options related to a former executive which accelerated vesting of 111,160 options and extended the exercise period from 90 days after termination to April 15, 2020.
	On April 16, 2015, the Luoxis and Vyrix subsidiaries were combined to form a company that was used to acquire Rosewind Corporation, a public company, through a reverse triangular merger. We anticipate the combined company will be reincorporated in Delaware with the name Aytu Bioscience, Inc.

Basis_of_Presentation_and_Busi1

Basis of Presentation and Business (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
	These unaudited financial statements represent the consolidated financial statements of Ampio Pharmaceuticals, Inc. (“Ampio” or “the Company”), and its wholly-owned subsidiaries, Vyrix Pharmaceuticals, Inc. (“Vyrix”) and Luoxis Diagnostics, Inc. (“Luoxis”), an 80.9% owned subsidiary. These unaudited consolidated financial statements should be read in conjunction with Ampio’s Annual Report on Form 10-K for the year ended December 31, 2014, which included all disclosures required by generally accepted accounting principles. In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary to present fairly the financial position of Ampio and its subsidiaries on a consolidated basis and the consolidated results of operations and cash flows for the interim periods presented. The results of operations for the period ended March 31, 2015 are not necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the period ended March 31, 2015 is unaudited. Ampio’s activities, being primarily research and development and raising capital, have not generated significant revenue to date.
Newly Issued Accounting Pronouncements	Newly Issued Accounting Pronouncements
	In January 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-01, “Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.” The purpose of this amendment is to eliminate the concept of extraordinary items. As a result, an entity will no longer be required to separately classify, present and disclose extraordinary events and transactions. The amendment is effective for annual reporting periods beginning after December 15, 2015 and subsequent interim periods with early application permitted. Management is currently assessing the impact the adoption of ASU 2015-01 will have on our financial statements.
	In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods beginning after December 15, 2016, with early adoption permitted. Management is currently assessing the impact the adoption of ASU 2014-15 will have on our financial statements.
	In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, “Revenue from Contracts with Customers”. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance will be effective for annual reporting periods beginning after December 15, 2016. Early adoption is not permitted. We are currently evaluating the accounting, transition and disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption.
Business	Business
	Ampio is a biopharmaceutical company focused primarily on developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depleting available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability. We are also focused on monetizing our sexual dysfunction portfolio and diagnostic platform.
Error in Classification	Error in Classification
	Patent costs were previously classified as research and development, however, it was determined that these costs were incorrectly classified and, therefore, have been reclassified as general and administrative expense for all periods presented. Patent costs consist of legal and filing fees related to obtaining and maintaining patents and should have been excluded from research and development activities as set forth in the FASB’s Accounting Standards Codification Topic 730, Research and Development. The impact of the correction of this error in classification decreased research and development expenses and correspondingly increased general and administrative expenses for the three months ended March 31, 2014 by $609,000. The correction of this error had no impact on our total operating expenses or our net loss for any periods presented.

Fixed_Assets_Tables

Fixed Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following:
		Estimated Useful	As of			As of
		Lives in years	March 31, 2015			December 31, 2014
	Manufacturing Facility/Clean Room - in progress	8	$	2,746,000		$	2,684,000
	Leasehold improvements	10		6,075,000			6,064,000
	Office furniture and equipment	3 - 10		556,000			556,000
	Lab equipment	5		1,076,000			1,060,000
	Less accumulated depreciation and amortization			(633,000	)		(419,000	)
	Fixed assets, net		$	9,820,000		$	9,945,000

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Summary of Commitments and Contingencies	Commitments and contingencies are described below and summarized by the following table:
		Total		Remaining		2016		2017		2018		2019		Thereafter
				2015
	Ampion supply agreement	$	9,799,000	$	2,149,000	$	2,550,000	$	2,550,000	$	2,550,000	$	—	$	—
	Clinical research and trial obligations		4,793,000		4,793,000		—		—		—		—		—
	Sponsored research agreement with related party		1,300,000		244,000		325,000		325,000		325,000		81,000		—
	Facility lease		3,147,000		223,000		297,000		306,000		316,000		326,000		1,679,000
		$	19,039,000	$	7,409,000	$	3,172,000	$	3,181,000	$	3,191,000	$	407,000	$	1,679,000
Rent Expense	Rent expense for the respective periods is as follows:
		Three Months Ended March 31,
		2015		2014
	Rent expense	$	67,000	$	30,000

Equity_Instruments_Tables

Equity Instruments (Tables)	3 Months Ended
	Mar. 31, 2015
Assumptions Used in Computing Fair Value of All Options Granted	the grants. Ampio has computed the fair value of all options granted during the three months ended March 31, 2015 using the following assumptions:
	Expected volatility		104	%
	Risk free interest rate		1.5	%
	Expected term (years)		5
	Dividend yield		0	%
Summary of Stock Options Outstanding and Exercisable	Stock options outstanding and exercisable at March 31, 2015 are summarized in the table below:
	Range of Exercise Prices	Number of			Weighted			Weighted Average
		Options			Average			Remaining
		Outstanding and			Exercise Price			Contractual Lives
		Exercisable
	$1.03 - $4.00		4,423,248		$	2.33			6.58
	$4.01 - $7.00		1,240,000		$	6.17			8.59
	$7.01 - $8.93		935,000		$	7.73			7.92
			6,598,248		$	3.82			7.15
Summary of Stock-Based Compensation Expense	value ratably over the vesting period. The following table summarizes stock-based compensation expense for the three months ended March 31, 2015 and 2014:
		Three Months Ended March 31,
		2015			2014
	Research and development expenses
	Stock options
	Ampio	$	608,000		$	638,000
	Luoxis		107,000			52,000
	Vyrix		8,000			29,000
	General and administrative expenses
	Common stock issued for services		30,000			30,000
	Stock options
	Ampio		537,000			299,000
	Luoxis		138,000			58,000
	Vyrix		19,000			(55,000	)
		$	1,447,000		$	1,051,000
	Unrecognized expense at March 31, 2015
	Ampio	$	2,623,000
	Luoxis	$	1,129,000
	Vyrix	$	194,000
	Weighted average remaining years to vest
	Ampio		1.07
	Luoxis		2.23
	Vyrix		1.79
Warrants Issued in Conjunction with its Senior Convertible Debentures	Ampio issued warrants in conjunction with its Senior Convertible Debentures, 2011 Private Placements and an underwritten public offering. A summary of all Ampio warrants is as follows:
		Number of			Weighted			Weighted Average
		Warrants			Average			Remaining
					Exercise Price			Contractual Life
	Outstanding December 31, 2014		516,329		$	3.26			1.44
	Warrants exercised - Private/Registered Direct Placements		(15,001	)	$	4.06
	Outstanding March 31, 2015		501,328		$	3.24			1.16
Ampio [Member]
Stock Option Activity	Ampio stock option activity is as follows:
		Number of			Weighted			Weighted Average		Aggregate Fair
		Options			Average			Remaining		Value
					Exercise Price			Contractual Life
	Outstanding December 31, 2014		6,568,248		$	3.82			7.66	$	17,090,000
	Granted		30,000		$	3.46
	Exercised		—		$	—
	Forfeited/Cancelled		—		$	—
	Outstanding March 31, 2015		6,598,248		$	3.82			7.15	$	17,169,000
	Exercisable at March 31, 2015		5,437,604		$	3.48			6.74	$	12,539,000
	Available for grant at March 31, 2015		3,717,773
Luoxis Diagnostics [Member]
Stock Option Activity	Luoxis stock option activity is as follows:
		Number of			Weighted			Weighted Average		Aggregate Fair
		Options			Average			Remaining		Value
					Exercise Price			Contractual Life
	Outstanding December 31, 2014		2,835,000		$	1.19			8.85	$	2,541,000
	Granted		—		$	—
	Exercised		—		$	—
	Forfeited/Cancelled		—		$	—
	Outstanding March 31, 2015		2,835,000		$	1.19			8.61	$	2,541,000
	Exercisable at March 31, 2015		975,000		$	1			8.26	$	687,000
	Available for grant at March 31, 2015		2,165,000
Vyrix Pharmaceuticals [Member]
Stock Option Activity	Vyrix stock option activity is as follows:
		Number of			Weighted			Weighted Average		Aggregate Fair
		Options			Average			Remaining		Value
					Exercise Price			Contractual Life
	Outstanding December 31, 2014		950,000		$	0.7			9.04	$	416,000
	Granted		—		$	—
	Exercised		—		$	—
	Forfeited/Cancelled		—		$	—
	Outstanding March 31, 2015		950,000		$	0.7			8.79	$	417,000
	Exercisable at March 31, 2015		475,000		$	0.7			8.79	$	208,000
	Available for grant at March 31, 2015		4,050,000

Segment_Information_Tables

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Schedule of Financial Information of Segments	Select financial information for our segments is as follows:
		Three Months Ended March 31,
		2015			2014
	Revenue:
	Ampio	$	—		$	—
	Combined Luoxis and Vyrix Company		21,000			13,000
	Consolidated revenue	$	21,000		$	13,000
	Consolidated net loss:
	Ampio	$	(5,749,000	)	$	(8,469,000	)
	Combined Luoxis and Vyrix Company		(1,842,000	)		(2,003,000	)
	Consolidated net loss		(7,591,000	)		(10,472,000	)
	Reconciliation of consolidated net loss attributable to Ampio:
	Net loss applicable to non-controlling interests		308,000			230,000
	Net loss attributable to Ampio	$	(7,283,000	)	$	(10,242,000	)
		March 31, 2015			December 31, 2014
	Total assets
	Ampio	$	52,419,000		$	61,326,000
	Combined Luoxis and Vyrix Company		10,202,000			8,942,000
	Total assets	$	62,621,000		$	70,268,000

Basis_of_Presentation_Business

Basis of Presentation, Business and Mergers - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2015
Business Acquisition [Line Items]
Increased general and administrative expenses	$609,000
Luoxis Diagnostics [Member]
Business Acquisition [Line Items]
Non controlling interest, ownership percentage by parent		80.90%

Summary_of_Significant_Account

Summary of Significant Accounting Policies - Schedule of Fixed Assets (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Less accumulated depreciation	($633,000)	($419,000)
Fixed assets, net	9,819,789	9,945,428
Manufacturing Facility/Clean Room - in progress [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years
Fixed assets, gross	2,746,000	2,684,000
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years
Fixed assets, gross	6,075,000	6,064,000
Office furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	556,000	556,000
Office furniture and equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Office furniture and equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Fixed assets, gross	$1,076,000	$1,060,000

Formation_of_Subsidiaries_Addi

Formation of Subsidiaries - Additional Information (Detail) (USD $)	3 Months Ended		1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	31-May-13	Dec. 31, 2014	Nov. 30, 2013
Subsidiary or Equity Method Investee [Line Items]
Gross proceeds from private placement		$68,442,553
Private placement shares issued	51,986,534				51,972,266
Estimated useful life of patent	15 years
In-process research and development	7,500,000				7,500,000	7,500,000
Patents						500,000
Trauma Research LLC [Member]
Subsidiary or Equity Method Investee [Line Items]
Cash paid for assignment of all diagnostic patent			330,000
Placement Agent [Member]
Subsidiary or Equity Method Investee [Line Items]
Net proceeds from private placement			3,980,000
Warrants issued to placement agent			313,000
Warrants issued to placement agent, shares			465,250
Warrant term	5 years
Exercise price of Warrant			$1
Luoxis Diagnostics [Member]
Subsidiary or Equity Method Investee [Line Items]
Gross proceeds from private placement			4,653,000
Private placement shares issued			4,652,500
Private placement per share			$1
Warrants issued to placement agent, shares				465,250
Exercise price of Warrant				$1
Luoxis Diagnostics [Member] | Parent [Member]
Subsidiary or Equity Method Investee [Line Items]
Non controlling interest, ownership percentage by parent	80.90%
Luoxis Diagnostics [Member] | Non-controlling Interest [Member]
Subsidiary or Equity Method Investee [Line Items]
Non controlling interest, ownership percentage by noncontrolling owners	19.10%
Luoxis Diagnostics [Member] | Placement Agent [Member]
Subsidiary or Equity Method Investee [Line Items]
Shares issued for assignment of all diagnostic patent			50,000
Common stock value issued for assignment of all diagnostic patent			$330,000
Warrant term				3 years 2 months 1 day

License_AgreementRevenue_Recog1

License Agreement/Revenue Recognition - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue Recognition [Line Items]
License revenue	$21,429	$12,500
Licensing Agreements [Member]
Revenue Recognition [Line Items]
License revenue	21,000	13,000
Korean Pharmaceutical [Member]
Revenue Recognition [Line Items]
Amount paid by supplier	500,000
Deferred revenue recognition period	10 years
Canadian Supplier [Member]
Revenue Recognition [Line Items]
Milestone payments earned and recognized	$250,000

Commitments_and_Contingencies_1

Commitments and Contingencies - Summary of Commitments and Contingencies (Detail) (USD $)	Mar. 31, 2015	Oct. 31, 2013
Commitment And Contingencies [Line Items]
Total	$19,039,000
2015	7,409,000
2016	3,172,000
2017	3,181,000
2018	3,191,000
2019	407,000
Thereafter	1,679,000
Ampion Supply Agreement [Member]
Commitment And Contingencies [Line Items]
Total	9,799,000	9,799,000
2015	2,149,000
2016	2,550,000
2017	2,550,000
2018	2,550,000
Clinical Research and Trial Obligations [Member]
Commitment And Contingencies [Line Items]
Total	4,793,000
2015	4,793,000
Sponsored Research Agreement With Related Party [Member]
Commitment And Contingencies [Line Items]
Total	1,300,000
2015	244,000
2016	325,000
2017	325,000
2018	325,000
2019	81,000
Facility Lease [Member]
Commitment And Contingencies [Line Items]
Total	3,147,000
2015	223,000
2016	297,000
2017	306,000
2018	316,000
2019	326,000
Thereafter	$1,679,000

Commitments_and_Contingencies_2

Commitments and Contingencies - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Oct. 31, 2013
Commitments and Contingencies [Line Items]
Total commitment	$19,039,000
Newly Leased Office Space and Manufacturing Facility [Member]
Commitments and Contingencies [Line Items]
Non-cancellable operating lease period	125 months
Non-cancellable operating lease initiation date	13-Dec-13
Non-cancellable operating lease effective date	1-May-14
Lease initial base rent per month	23,000
Total base rent over the term of the lease	3,300,000
Sponsored Research Agreement With Related Party [Member]
Commitments and Contingencies [Line Items]
Total commitment	1,300,000
Lease expiration date	Mar-19
Sponsored Research Agreement termination notice period	180 days
Minimum [Member]
Commitments and Contingencies [Line Items]
Equipment lease payments net	264,000
Maximum [Member]
Commitments and Contingencies [Line Items]
Equipment lease payments net	325,000
Ampion Study Production [Member] | Clinical Research Obligations [Member]
Commitments and Contingencies [Line Items]
Commitment remain under terms of clinical research agreement	2,000,000
Optina Study Trial [Member] | Clinical Research Obligations [Member]
Commitments and Contingencies [Line Items]
Remaining contract commitments related to trial expense	2,793,000
Ampion Supply Agreement [Member]
Commitments and Contingencies [Line Items]
Total commitment	$9,799,000	$9,799,000

Commitments_and_Contingencies_3

Commitments and Contingencies - Rent Expense (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$67,000	$30,000

Common_Stock_Additional_Inform

Common Stock - Additional Information (Detail) (USD $)	3 Months Ended		0 Months Ended	1 Months Ended
	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2014
Components Of Common Stock [Line Items]
Common Stock, shares authorized		100,000,000			100,000,000
Common Stock, par value		$0.00			$0.00
Preferred Stock, shares authorized		10,000,000			10,000,000
Preferred Stock, par value		$0.00			$0.00
Remaining common stocks and warrants under shelf registration					$86,300,000
Common Stock, shares issued		51,986,534			51,972,266
Gross proceeds from issuance of common stock	68,442,553
Non Employee Directors [Member] | Common Stock [Member]
Components Of Common Stock [Line Items]
Issuance of common stock for services, shares	4,209	7,998
Issuance of common stock for services	30,000	30,000
Underwritten Public Offering [Member]
Components Of Common Stock [Line Items]
Common Stock, par value	$7		$7
Common Stock, shares issued	9,775,000		9,775,000
Gross proceeds from issuance of common stock			68,400,000
Net proceeds from issuance of common stock			63,400,000
Shelf Registration [Member]
Components Of Common Stock [Line Items]
Common stock and warrants				$100,000,000
Common stock to be sold by directors and management in future public offerings				1,500,000

Equity_Instruments_Additional_

Equity Instruments - Additional Information (Detail) (USD $)	3 Months Ended	1 Months Ended
	Mar. 31, 2015	Mar. 31, 2013	31-May-13	Jun. 15, 2013	Dec. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeiture rate	5.00%
Number of Options, Granted	30,000
Stock options exercise price	$3.46
Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued to placement agent, shares		465,250
Exercise price of Warrant		$1
Warrant term	5 years
Luoxis 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance				5,000,000
Vyrix 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance	5,000,000
Ampio March 2010 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance					11,700,000
Luoxis Diagnostics [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Granted	0
Stock options exercise price	$0
Warrants issued to placement agent, shares			465,250
Exercise price of Warrant			$1
Luoxis Diagnostics [Member] | Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant term			3 years 2 months 1 day

Equity_Instruments_Assumptions

Equity Instruments - Assumptions Used in Computing Fair Value of All Options Granted (Detail)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected volatility	104.00%
Risk free interest rate	1.50%
Expected term (years)	5 years
Dividend yield	0.00%

Equity_Instruments_Ampio_Stock

Equity Instruments - Ampio Stock Option Activity (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Granted	30,000
Weighted Average Exercise Price, Granted	$3.46
Ampio [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance	6,568,248
Number of Options, Granted	30,000
Number of Options, Exercised	0
Number of Options, Forfeited/Cancelled	0
Number of Options, Ending Balance	6,598,248	6,568,248
Number of Options, Exercisable	5,437,604
Number of Options, Available for grant	3,717,773
Weighted Average Exercise Price, Beginning Balance	$3.82
Weighted Average Exercise Price, Granted	$3.46
Weighted Average Exercise Price, Exercised	$0
Weighted Average Exercise Price, Forfeited/Cancelled	$0
Weighted Average Exercise Price, Ending Balance	$3.82	$3.82
Weighted average exercise price, Exercisable	$3.48
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Outstanding	7 years 1 month 24 days	7 years 7 months 28 days
Weighted Average Remaining Contractual Life, Exercisable	6 years 8 months 27 days
Aggregate Fair Value, Beginning Balance	$17,090,000
Aggregate Fair Value, Ending Balance	17,169,000	17,090,000
Aggregate Fair Value, Exercisable	$12,539,000

Equity_Instruments_Summary_of_

Equity Instruments - Summary of Stock Options Outstanding and Exercisable (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding and Exercisable	6,598,248
Weighted Average Exercise Price	$3.82
Weighted Average Remaining Contractual Lives	7 years 1 month 24 days
$1.03 - $4.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices Lower	$1.03
Range of Exercise Prices Upper	$4
Number of Options Outstanding and Exercisable	4,423,248
Weighted Average Exercise Price	$2.33
Weighted Average Remaining Contractual Lives	6 years 6 months 29 days
$4.01 - $7.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices Lower	$4.01
Range of Exercise Prices Upper	$7
Number of Options Outstanding and Exercisable	1,240,000
Weighted Average Exercise Price	$6.17
Weighted Average Remaining Contractual Lives	8 years 7 months 2 days
$7.01 - $8.93 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices Lower	$7.01
Range of Exercise Prices Upper	$8.93
Number of Options Outstanding and Exercisable	935,000
Weighted Average Exercise Price	$7.73
Weighted Average Remaining Contractual Lives	7 years 11 months 1 day

Equity_Instruments_Luoxis_Stoc

Equity Instruments - Luoxis Stock Option Activity (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Granted	30,000
Weighted Average Exercise Price, Granted	$3.46
Luoxis Diagnostics [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance	2,835,000
Number of Options, Granted	0
Number of Options, Exercised	0
Number of Options, Forfeited/Cancelled	0
Number of Options, Ending Balance	2,835,000	2,835,000
Number of Options, Exercisable	975,000
Number of Options, Available for grant	2,165,000
Weighted Average Exercise Price, Beginning Balance	$1.19
Weighted Average Exercise Price, Granted	$0
Weighted Average Exercise Price, Exercised	$0
Weighted Average Exercise Price, Forfeited/Cancelled	$0
Weighted Average Exercise Price, Ending Balance	$1.19	$1.19
Weighted average exercise price, Exercisable	$1
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Outstanding	8 years 7 months 10 days	8 years 10 months 6 days
Weighted Average Remaining Contractual Life, Exercisable	8 years 3 months 4 days
Aggregate Fair Value, Beginning Balance	$2,541,000
Aggregate Fair Value, Ending Balance	2,541,000	2,541,000
Aggregate Fair Value, Exercisable	$687,000

Equity_Instruments_Vyrix_Stock

Equity Instruments - Vyrix Stock Option Activity (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Granted	30,000
Weighted Average Exercise Price, Granted	$3.46
Vyrix Pharmaceuticals [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance	950,000
Number of Options, Granted	0
Number of Options, Exercised	0
Number of Options, Forfeited/Cancelled	0
Number of Options, Ending Balance	950,000	950,000
Number of Options, Exercisable	475,000
Number of Options, Available for grant	4,050,000
Weighted Average Exercise Price, Beginning Balance	$0.70
Weighted Average Exercise Price, Granted	$0
Weighted Average Exercise Price, Exercised	$0
Weighted Average Exercise Price, Forfeited/Cancelled	$0
Weighted Average Exercise Price, Ending Balance	$0.70	$0.70
Weighted average exercise price, Exercisable	$0.70
Weighted Average Remaining Contractual Life, Outstanding	8 years 9 months 15 days	9 years 15 days
Weighted Average Remaining Contractual Life, Exercisable	8 years 9 months 15 days
Aggregate Fair Value, Beginning Balance	$416,000
Aggregate Fair Value, Ending Balance	417,000	416,000
Aggregate Fair Value, Exercisable	$208,000

Equity_Instruments_Summary_of_1

Equity Instruments - Summary of Stock-Based Compensation Expense (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$1,447,000	$1,051,000
Ampio [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized expense at March 31, 2015	2,623,000
Weighted average remaining years to vest	1 year 26 days
Luoxis Diagnostics [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized expense at March 31, 2015	1,129,000
Weighted average remaining years to vest	2 years 2 months 23 days
Vyrix Pharmaceuticals [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized expense at March 31, 2015	194,000
Weighted average remaining years to vest	1 year 9 months 15 days
Research and Development Expenses [Member] | Stock Options [Member] | Ampio [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	608,000	638,000
Research and Development Expenses [Member] | Stock Options [Member] | Luoxis Diagnostics [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	107,000	52,000
Research and Development Expenses [Member] | Stock Options [Member] | Vyrix Pharmaceuticals [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	8,000	29,000
General and Administrative Expenses [Member] | Stock Options [Member] | Ampio [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	537,000	299,000
General and Administrative Expenses [Member] | Stock Options [Member] | Luoxis Diagnostics [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	138,000	58,000
General and Administrative Expenses [Member] | Stock Options [Member] | Vyrix Pharmaceuticals [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	19,000	-55,000
General and Administrative Expenses [Member] | Common Stock Issued for Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$30,000	$30,000

Equity_Instruments_Warrants_Is

Equity Instruments - Warrants Issued in Conjunction with its Senior Convertible Debentures (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Number of Warrants Outstanding
Number of Warrants Outstanding, Beginning Balance	516,329
Number of Warrants Outstanding, Ending Balance	501,328	516,329
Warrants, Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$3.26
Weighted Average Exercise Price, Outstanding Ending Balance	$3.24	$3.26
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Warrants Outstanding	1 year 1 month 28 days	1 year 5 months 9 days
Registered Direct Placements [Member]
Number of Warrants Outstanding
Number of Warrants, Exercised	-15,001
Warrants, Weighted Average Exercise Price
Weighted Average Exercise Price, Warrants Exercised	$4.06

Equity_Instruments_Significant

Equity Instruments - Significant Assumptions (Detail)	3 Months Ended
	Mar. 31, 2015
Assumptions used to Determine Fair Value Options [Line Items]
Expected volatility	104.00%
Risk free interest rate	1.50%
Expected term (years)	5 years
Dividend yield	0.00%
Ampio [Member]
Assumptions used to Determine Fair Value Options [Line Items]
Expected volatility	72.00%
Risk free interest rate	0.25%
Expected term (years)	5 years
Dividend yield	0.00%
Luoxis Diagnostics [Member]
Assumptions used to Determine Fair Value Options [Line Items]
Expected volatility	87.00%
Risk free interest rate	0.52%
Expected term (years)	5 years
Dividend yield	0.00%

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Consideration for services related to research and development	($1,340,000)
First Installment [Member] | Scenario, Plan [Member]
Related Party Transaction [Line Items]
Equipment lease payments net		325,000
Consideration for services related to research and development		725,000
Contract term		60 months 15 days
Lease expiration date		Mar-19
Second Installment [Member] | Scenario, Plan [Member]
Related Party Transaction [Line Items]
Equipment lease payments net		615,000
Second Installment [Member] | After Amendment [Member] | Scenario, Plan [Member]
Related Party Transaction [Line Items]
Monthly equipment lease payments		6,000
Stockholders [Member]
Related Party Transaction [Line Items]
Advance to stockholders		$91,000	$91,000

Segment_Information_Additional

Segment Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015
	Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segment_Information_Schedule_o

Segment Information - Schedule of Financial Information of Segments (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Segment Reporting Information [Line Items]
Revenue	$21,429	$12,500
Contribution loss	-7,591,420	-10,471,762
Net loss applicable to non-controlling interests	307,837	229,579
Total assets	62,620,451	70,268,000	70,268,410
Net loss attributable to Ampio	-7,283,583	-10,242,183
Ampio [Member]
Segment Reporting Information [Line Items]
Contribution loss	-5,749,000	-8,469,000
Total assets	52,419,000	61,326,000
Combined Luoxis and Vyrix Company [Member]
Segment Reporting Information [Line Items]
Revenue	21,000	13,000
Contribution loss	-1,842,000	-2,003,000
Total assets	$10,202,000	$8,942,000

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail)	0 Months Ended	3 Months Ended
	Apr. 15, 2015	Mar. 31, 2015
Subsequent Event [Member]
Subsequent Event [Line Items]
Option related to former executive	111,160
Extended exercise period	90 days
Accelerated vesting, expiration date	15-Apr-20
Rosewind Corporation [Member]
Subsequent Event [Line Items]
Date of acquisition		16-Apr-15